I-Rimegepant yi-molecule encinci inhibitor yecalcitonini-peptide ehlobene ne-gene (CGRP) i-receptor evimba isenzo se-CGRP, i-vasodilator enamandla ekholelwa ukuba idlala indima kwintloko ye-migraine.I-Rimegepant ivunyiwe kunyango lwe-acute migraine attack.Kulingo lweklinikhi, i-rimegepant yayinyamezeleke gabalala ngeemeko ezinqabileyo kuphela zokunyuka kwe-serum aminotransferase okwethutyana ngexesha lonyango kwaye akukho ziganeko zixeliweyo zokwenzakala kwesibindi okubonakalayo.

I-Rimegepant ngumchasi womlomo we-CGRP receptor eyenziwe yi-Biohaven Pharmaceuticals.Ifumene imvume ye-FDA nge-27 kaFebruwari 2020 yonyango oluqatha lwentloko yentloko.Ngelixa abachasi abaninzi be-CGRP kunye ne-receptor yayo bavunyiwe kunyango lwe-migraine (umz. [erenumab], [fremanezumab], [galcanezumab]), i-rimegepant kunye [ubrogepant] ngamalungu kuphela osapho lwe "gepants" lwamayeza aseleyo kuphuhliso, kwaye kuphela abachasi beCGRP abanobukhona be-oral bioavailability.Umgangatho wangoku wonyango lwe-migraine ubandakanya unyango lokukhupha isisu kunye ne "triptans", ezifana [sumatriptan], kodwa la mayeza anqatshelwe kwizigulane ezine-cerebrovascular and cardiovascular disease esele zikhona ngenxa yeempawu zabo ze-vasoconstrictive.I-Antagonism ye-CGRP yendlela iye yaba yinto ekujoliswe kuyo ekhangayo yonyango lwe-migraine njengoko, ngokungafaniyo ne-triptans, abachasi be-CGRP bomlomo ababoni iimpawu ze-vasoconstrictive kwaye ngoko ke zikhuselekile ukusetyenziswa kwizigulane ezine-contraindications kunyango oluqhelekileyo.

IRimegepant yiCalcitoninI-Gene-related Receptor Antagonist.Indlela yokwenza i-rimegepant ifana ne-aCalcitoninI-Gene-related Receptor Antagonist.